US FDA to study visual distractions in DTC TV ads
This article was originally published in Scrip
A US FDAstudy on visual distractions in direct-to-consumer television commercials will aid the agency in interpreting the FDA Amendments Act's requirement that the major statement of risks be presented in a "clear, conspicuous and neutral" manner. Under FDAAA, the agency must develop regulations by March 2010 on standards for determining whether side-effect and contraindication information is presented in this manner. The study is also aimed at evaluating whether use of competing, compelling visuals about a drug's benefits interfere with viewers' processing and comprehension of risk information, and whether compelling visuals affect the way consumers think about a branded product. The agency has revised its initial plans for the study, first announced in August 2007, from a mall-intercept to an internet-administered procedure, and has doubled the sample size to 2,400 respondents, who will view commercials for a fictitious blood pressure medicine.
You may also be interested in...
There are 18 people on the committee that will issue the first recommendations on COVID-19 vaccine development and licensure. Among the experts are a University of Michigan epidemiologist who will serve as acting chairman and seven temporary voting members, two of whom required conflict-of-interest waivers.
Unlike AMAG's Makena, nearly all the products that have seen their accelerated approvals pulled have left the market quietly, our infographic shows.
CBER’s Peter Marks says agency assesses the importance of durability of effect differently for a gene therapy that treats a disease that has no other available therapies versus a condition for which there are multiple approved treatments. Marks’ comments shed more light on the complete response letter for BioMarin’s hemophilia gene therapy Roctavian.